Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
| Autor: | Bo Xu, Target Ac Investigators, Yuichi Saito, Volker Schächinger, Henning Kelbæk, Marie-Angèle Morel, Alexandra Lansky, William Wijns, Ming Zheng, Richard Anderson, Andreas Baumbach |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Target lesion medicine.medical_specialty Time Factors medicine.medical_treatment Coronary Artery Disease 030204 cardiovascular system & hematology Prosthesis Design Risk Assessment law.invention 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Randomized controlled trial Risk Factors law Absorbable Implants Coronary stent medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Everolimus 030212 general & internal medicine Myocardial infarction Aged business.industry Stent Cardiovascular Agents Drug-Eluting Stents General Medicine Middle Aged medicine.disease Surgery Europe Treatment Outcome Drug-eluting stent Sirolimus Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Catheterization and Cardiovascular Interventions. 96:1023-1028 |
| ISSN: | 1522-726X 1522-1946 |
| DOI: | 10.1002/ccd.28609 |
| Popis: | Background The Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel biodegradable polymer sirolimus-eluting coronary stent has been evaluated in the randomized TARGET I trial in which low-risk patients were enrolled with strict eligibility criteria. Recently, the TARGET All Comers study has shown similar results of the Firehawk compared to the XIENCE stent (Abbott Vascular, Santa Clara). However, clinical outcomes in high-risk patients are unclear. Methods The TARGET All Comer study was a randomized trial that assigned patients to either Firehawk or XIENCE implantation. This TARGET AC subanalysis sought to evaluate the 2 year clinical outcomes of patients according to two risk groups; patients meeting all inclusion criteria and no exclusion criteria of the TARGET I trial were classified as "low-risk," while their counterparts were classified as "high-risk." The primary endpoint was target lesion failure. Results A total of 1,585 patients were included, of which 1,334 (84%) were classified as high-risk. At 2 years, the high-risk group had a significantly higher rate of TLF than the low-risk group (9.5% vs. 3.6%, p = .003), mainly driven by increased target vessel myocardial infarction (6.3% vs. 2.4%, p = .02). The Firehawk and XIENCE had no significant differences in TLF among both low-risk (3.1% vs. 4.2%, p = .66) and high-risk (9.9% vs. 9.1%, p = .57) patients. Conclusions High-risk patients had worse clinical outcomes at 2 years in the TARGET All Comer study. Outcomes with the Firehawk were similar to the XIENCE stent among both low-risk and high-risk patients at 2 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text